HomeAbout SNHPAMembership InformationCorporate PartnersMembers OnlyEvents340B ResourcesAdvocacyCareers/Rx Job SolutionsLinksNews
Welcome, Guest!
Member
Login:
Forgot your
password?
Home
About SNHPA
Membership Information
Corporate Partners
Members Only
Events
340B Resources
Advocacy
Rx Job Solutions
Links
News
Search SNHPA

 Home > Advocacy
Advocacy

SNHPA monitors, educates, and serves as an advocate on federal legislative and regulatory issues related to drug pricing and other pharmacy matters affecting safety-net providers.  When Congress was creating the 340B program in 1992, SNHPA took the lead role in ensuring that hospitals were included in the program and the organization has been representing the interests of 340B hospitals ever since.  The following are some of the legislative issues that SNHPA is focusing on:

Advocacy Goals
  • Extend 340B discounts to hospital inpatient settings which would significantly reduce costs and remove administrative burdens.
  • Address proposed government guidelines that would significantly restrict the use of the 340B program by narrowing the definition of "patient" under the program.
  • Ensure smooth and expedited enrollment for newly eligible 340B hospitals.
  • Educate hospitals and states about exemption from mandate to collect rebates on drugs administered by health professionals in hospital outpatient settings.
  • Advocate for expedited implementation of 340B reform law’s integrity provisions to improve program oversight, administration, and compliance; recover 340B overpayments; make 340B prices available to covered entities.
  • Ensure Office of Pharmacy Affairs has proper funding to effectively administer 340B program.
  • Ensure that 340B health facilities are able to implement new federal guidelines allowing providers to expand use of contract pharmacy arrangements.
  • Advocate for adequate reimbursement from Medicaid, Medicare and third party payers.
  • Address problems in accessing IVIG and other products at federally required 340B-discounted pricing
  • Repeal the Orphan Drug Exemption that prohibits certain 340B hospitals from obtaining discounts on certain drugs deemed "orphan" by the U.S. Food & Drug Administration.
SNHPA Endorsed Legislation
111th Congress
  • The 340B Program Improvement and Integrity Act of 2009 (HR 444)
  • The 340B Program Improvement and Integrity Act of 2009 (S. 1239)
110th Congress
If you have questions, please contact SNHPA Government Relations Director Rob Recklaus at rob.recklaus@safetynetrx.org or 202-552-5852 or SNHPA Policy and Advocacy Manager Jaimie Vickery at jaimie.vickery@safetynetrx.org or 202-552-5855.
 
Drug Discount Monitor
Untitled Document

PLATINUM CORPORATE PARTNERS
American Health Care

Cardinal Health
AmerisourceBergen Drug Company

AmerisourceBergen Solutions Group

Pharmacy Healthcare Solutions
Coordinated Care Network

McKesson

NEChealth Network

Pharmaceutical Strategies Group
Sentry Data Systems

Talyst

Wellpartner, Inc.

GOLD CORPORATE PARTNERS

Comprehensive Pharmacy Services CVS Caremark EXPRESS SCRIPTS Macro Helix PDX-NHIN-Rx.com SUNRx

SILVER CORPORATE PARTNERS

ESI

NON-PROFIT AFFILIATES




1501 M Street NW 7th Floor Washington, DC 20005 Phone: 202-552-5850 Fax: 202-552-5868

© Copyright 2010 Safety Net Hospitals for Pharmaceutical Access